Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AtriCure, Inc.ATRC · Entity 2704 | Director | May 18, 2026 | May 20, 2026 |
| ClearPoint Neuro, Inc.CLPT · Entity 2367 | Director | May 21, 2026 | May 26, 2026 |
| PIPER SANDLER COMPANIESPJC · Entity 3863 | Director | December 13, 2019 | December 16, 2019 |
| ViewRay, Inc.VRAY · Entity 111118 | Director | July 21, 2023 | July 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AtriCure, Inc.
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,954 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Grant · Acquired 6,144 · Balance 55,954 F1: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.
ClearPoint Neuro, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,820 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 12,820 · Balance 12,820 F1: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock.
F2: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2027 annual meeting of stockholders.
PIPER SANDLER COMPANIES
Report date December 13, 2019 · Filed December 16, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,794 |
Reported balance
After 2019-12-13 transaction · row 1
1 source rowRow 1 · 2019-12-13 · Grant · Acquired 9 · Balance 11,794 F1: Dividend equivalents that are paid on shares of phantom stock are deemed reinvested in additional shares of phantom stock as of the payment date. These phantom shares accrue to the reporting person's account in the directors' deferred compensation plan. The shares of phantom stock become payable, in an equal number of shares of common stock, on the last day of the year in which the reporting person's service as a director terminates. |
| Common StockSEC Table I · non-derivative | IndirectBy IRA | 1,200 |
Reported balance
Holding disclosure · report date 2019-12-13 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,200 |
| Common StockSEC Table I · non-derivative | IndirectBy B. Kristine Johnson Trust | 2,578 |
Reported balance
Holding disclosure · report date 2019-12-13 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,578 |
Filing footnotes · ownership attribution and instrument terms
F1: Dividend equivalents that are paid on shares of phantom stock are deemed reinvested in additional shares of phantom stock as of the payment date. These phantom shares accrue to the reporting person's account in the directors' deferred compensation plan. The shares of phantom stock become payable, in an equal number of shares of common stock, on the last day of the year in which the reporting person's service as a director terminates.
ViewRay, Inc.
Report date July 21, 2023 · Filed July 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,720 |
Reported balance
After 2023-07-21 transaction · row 1
1 source rowRow 1 · 2023-07-21 · Sale · Disposed 30,702 · Balance 126,720 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.051 to $0.053, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range stated. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.051 to $0.053, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range stated.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Paragon 28, Inc.
Report date April 21, 2025 · Filed April 21, 2025
Section 16 reporting ended · disclosed 2025-04-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-21 transaction · row 1
1 source rowRow 1 · 2025-04-21 · Disposition to issuer · Disposed 47,347 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated January 28, 2025 (the "Merger Agreement"), by and among the Issuer, Zimmer Biomet Holdings, Inc., Zimmer, Inc. ("Parent"), and Gazelle Merger Sub I, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $13.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $1.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent, Equiniti Trust Company, LLC, as rights agent, and, for certain provisions, Zimmer Biomet Holdings, Inc., as guarantor. F3: At the Effective Time, each outstanding restricted stock unit solely subject to time-based vesting conditions vested and was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award, (x) the Cash Consideration and (y) one CVR. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated January 28, 2025 (the "Merger Agreement"), by and among the Issuer, Zimmer Biomet Holdings, Inc., Zimmer, Inc. ("Parent"), and Gazelle Merger Sub I, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time").
F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $13.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $1.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent, Equiniti Trust Company, LLC, as rights agent, and, for certain provisions, Zimmer Biomet Holdings, Inc., as guarantor.
F3: At the Effective Time, each outstanding restricted stock unit solely subject to time-based vesting conditions vested and was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award, (x) the Cash Consideration and (y) one CVR.
SPECTRANETICS CORP
Report date August 09, 2017 · Filed August 11, 2017
Section 16 reporting ended · disclosed 2017-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| SPNC Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-08-09 transaction · row 1
1 source rowRow 1 · 2017-08-09 · Disposition to issuer · Disposed 31,219 · Balance 0 F1: Per the terms of the Agreement and Plan of Merger, dated as of June 27, 2017, among the Company, Philips Holding USA Inc., a Delaware corporation, and HealthTech Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock other than the restricted common stock described in Note 2 was validly tendered for $38.50 per share in cash, without interest and less any required withholding taxes. F2: Includes 4,780 shares of restricted common stock that, pursuant to their terms upon consummation of the Merger Agreement, were canceled at the Effective Time (as defined in the Merger Agreement) and converted into the right to receive $38.50 per share in cash, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Per the terms of the Agreement and Plan of Merger, dated as of June 27, 2017, among the Company, Philips Holding USA Inc., a Delaware corporation, and HealthTech Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock other than the restricted common stock described in Note 2 was validly tendered for $38.50 per share in cash, without interest and less any required withholding taxes.
F2: Includes 4,780 shares of restricted common stock that, pursuant to their terms upon consummation of the Merger Agreement, were canceled at the Effective Time (as defined in the Merger Agreement) and converted into the right to receive $38.50 per share in cash, without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 26, 2026 20:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 12,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-239426 · ownership.xml · derivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,820 Underlying: Common Stock · 12,820 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2027 annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2027 annual meeting of stockholders. Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 12,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-234569 · ownership.xml · derivative · entry 2 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 12,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-234569 · ownership.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| May 18, 2026 Filed May 20, 2026 13:25 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 6,144 | $0.00 | $0.00 |
DisclosureSEC source: 0001231984-26-000002 · wk-form4_1779283531.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,954 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 22, 2025 Filed May 23, 2025 22:07 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 12,417 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-077186 · ownership.xml · derivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,417 Underlying: Common Stock · 12,417 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. Read SEC document |
| May 19, 2025 Filed May 21, 2025 20:42 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 5,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-25-000061 · wk-form4_1747860128.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,810 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 16, 2025 Filed May 19, 2025 20:45 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 21,093 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-074466 · ownership.xml · derivative · entry 2 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,093 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| May 16, 2025 Filed May 19, 2025 20:45 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 21,093 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-074466 · ownership.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| April 21, 2025 Filed Apr 21, 2025 21:00 UTC | Paragon 28, Inc. FNA · Entity 80621 | Disposition to issuerCommon Stock | 47,347 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-056366 · ownership.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated January 28, 2025 (the "Merger Agreement"), by and among the Issuer, Zimmer Biomet Holdings, Inc., Zimmer, Inc. ("Parent"), and Gazelle Merger Sub I, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time"). F2 · price: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $13.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $1.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent, Equiniti Trust Company, LLC, as rights agent, and, for certain provisions, Zimmer Biomet Holdings, Inc., as guarantor. F3 · price: At the Effective Time, each outstanding restricted stock unit solely subject to time-based vesting conditions vested and was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award, (x) the Cash Consideration and (y) one CVR. Read SEC document |
| May 17, 2024 Filed May 21, 2024 20:49 UTC | Paragon 28, Inc. FNA · Entity 80621 | GrantCommon Stock | 15,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000253 · form4.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,347 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) the first anniversary of grant date and (ii) immediately before the Annual Meeting following the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:24 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 21,093 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-24-000068 · wk-form4_1715977444.xml · derivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,093 Underlying: Common Stock · 21,093 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. Read SEC document |
| May 14, 2024 Filed May 15, 2024 13:18 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 17,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-24-000055 · wk-form4_1715779095.xml · derivative · entry 2 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,153 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On May 25, 2023, the reporting person was granted 17,153 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders. F2 · derivative.expiration_date: On May 25, 2023, the reporting person was granted 17,153 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders. Read SEC document |
| May 14, 2024 Filed May 15, 2024 13:18 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 17,153 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001285550-24-000055 · wk-form4_1715779095.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 13, 2024 Filed May 14, 2024 21:05 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 7,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-24-000082 · wk-form4_1715720728.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,409 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| July 21, 2023 Filed Jul 24, 2023 20:14 UTC | ViewRay, Inc. VRAY · Entity 111118 | SaleCommon Stock | 30,702 | $0.05 | $1,596.50 |
DisclosureSEC source: 0001628280-23-025462 · wk-form4_1690229646.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,720 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.051 to $0.053, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range stated. Read SEC document |
| July 18, 2023 Filed Jul 21, 2023 00:36 UTC | ViewRay, Inc. VRAY · Entity 111118 | SaleCommon Stock | 79,622 | $0.07 | $5,653.16 |
DisclosureSEC source: 0001628280-23-025276 · wk-form4_1689899749.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,422 Read SEC document |
| May 25, 2023 Filed May 26, 2023 18:09 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 17,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-23-000058 · wf-form4_168512454525270.xml · derivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,153 Underlying: Common Stock · 17,153 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:15 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 3,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-23-000059 · wk-form4_1685132069.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,621 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 17, 2023 Filed May 19, 2023 22:33 UTC | Paragon 28, Inc. FNA · Entity 80621 | GrantCommon Stock | 8,361 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000058 · form4.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,441 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) the first anniversary of grant date and (ii) immediately before the Annual Meeting following the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 22:58 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 431 | $7.97 | $3,435.07 |
DisclosureSEC source: 0001285550-23-000005 · wf-form4_167287306641198.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,453 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $7.97 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ending December 30, 2022. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 22:17 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 337 | $10.19 | $3,434.03 |
DisclosureSEC source: 0001285550-22-000061 · wf-form4_166492181090364.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,022 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $10.19 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ending September 30, 2022. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 18:38 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 272 | $12.63 | $3,435.36 |
DisclosureSEC source: 0001285550-22-000032 · wf-form4_165713269383762.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,685 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $12.63 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ending June 30, 2022. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:10 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 54,511 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-017227 · wf-form4_165532379190564.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,044 F1 · shares: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on June 13, 2023, subject to the Reporting Person remaining a service provider through such date. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:34 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 6,179 | $0.00 Strike: $9.71 | $0.00 |
DisclosureSEC source: 0001420506-22-001143 · doc4_1010.xml · derivative · entry 2 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,179 Underlying: Common Stock · 6,179 shares Expires 2032-05-25 F2 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2023 annual meeting of stockholders. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:34 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 9,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001420506-22-001143 · doc4_1010.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,413 F1 · price: The shares are restricted stock and will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2023 annual meeting of stockholders. Read SEC document |
| May 25, 2022 Filed May 27, 2022 13:05 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 3,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001323885-22-000079 · wf-form4_165365668922346.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,435 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 18, 2022 Filed May 20, 2022 21:05 UTC | Paragon 28, Inc. FNA · Entity 80621 | GrantCommon Stock | 8,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011424 · doc1.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,080 F1 · shares: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) the first anniversary of grant date and (ii) immediately before the Annual Meeting following the grant date, subject to the Reporting Person's continued service to the issuer. Read SEC document |
| May 12, 2022 Filed May 13, 2022 00:25 UTC | ViewRay, Inc. VRAY · Entity 111118 | PurchaseCommon Stock | 40,000 | $2.82 | $112,704.00 |
DisclosureSEC source: 0001628280-22-014197 · wf-form4_165240149513917.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,533 Read SEC document |
| May 12, 2022 Filed May 13, 2022 13:45 UTC Amendment | ViewRay, Inc. VRAY · Entity 111118 | PurchaseCommon Stock | 40,000 | $2.82 | $112,704.00 |
DisclosureSEC source: 0001628280-22-014238 · wf-form4a_165244951068759.xml · nonDerivative · entry 3 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 40,000 F1 · ownership.direct: On May 12, 2022, the reporting person filed a Form 4 that inadvertently reported that the reporting person acquired shares of common stock directly. In fact, the shares were acquired by the reporting person's spouse. This amendment reflects the indirect ownership of the acquired shares. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:05 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 345 | $9.96 | $3,436.20 |
DisclosureSEC source: 0001171520-22-000235 · eps10156.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,144 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $9.96 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2022. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:08 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 10,806 | $5.83 | $62,998.98 |
DisclosureSEC source: 0001628280-22-000347 · wf-form4_164142050259400.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,533 F1 · shares: The reported securities are DSUs that entitle the Reporting Person to receive one share of Common Stock per DSU upon the earliest of (i) the Reporting Person's termination of service from the Issuer's board of directors, (ii) a Change of Control of the Issuer as defined in the Issuer's Amended & Restated 2015 Equity Incentive Award Plan or (iii) January 3, 2032 (the tenth anniversary of the grant date). 1/12th of these DSUs shall vest on the last day of each calendar month beginning on January 31, 2022 such that 100% of the DSUs will be vested on December 31, 2022, subject to the Reporting Person remaining a service provider through each such vesting date. F2 · price: These DSUs were issued to the reporting person pursuant to ViewRay Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $63,000. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 12:18 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 595 | $11.54 | $6,866.30 |
DisclosureSEC source: 0001171520-22-000016 · doc4_991.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,799 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $11.54 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2021. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 21:33 UTC | Paragon 28, Inc. FNA · Entity 80621 | GrantCommon Stock | 14,162 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-021599 · doc1.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,162 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs shall vest on each anniversary of December 1, 2021, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 14,162 RSUs. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:14 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 383 | $17.92 | $6,863.36 |
DisclosureSEC source: 0001420506-21-001361 · doc4_972.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,204 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $17.92 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended October 1, 2021. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:17 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 257 | $20.26 | $5,206.82 |
DisclosureSEC source: 0001420506-21-000846 · doc4_937.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,821 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $20.26 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 30, 2021. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 12:34 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 6,006 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001171520-21-000263 · ownership.xml · derivative · entry 2 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,006 Underlying: Common Stock · 6,006 shares Expires 2031-06-25 F2 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2022 annual meeting of stockholders. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 12:34 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 3,003 | $0.00 | $0.00 |
DisclosureSEC source: 0001171520-21-000263 · ownership.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,564 F1 · shares: The shares are restricted stock and will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2022 annual meeting of stockholders. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:27 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 19,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040915 · doc4.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,727 F1 · shares: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on June 14, 2022, subject to the Reporting Person remaining a service provider through such date. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:46 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 1,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035353 · doc4.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,871 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 20:02 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 255 | $19.57 | $4,990.35 |
DisclosureSEC source: 0001420506-21-000376 · doc4_917.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,561 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $19.57 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2021. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 23:35 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 333 | $15.00 | $4,995.00 |
DisclosureSEC source: 0001420506-21-000008 · doc4_892.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,306 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $15.00 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2020. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 22:11 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 876 | $5.71 | $5,001.96 |
DisclosureSEC source: 0001420506-20-001039 · doc4_859.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,973 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $5.71 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2020. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 17:32 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,406 | $3.55 | $4,991.30 |
DisclosureSEC source: 0001171520-20-000289 · doc4_820.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,097 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.55 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 30, 2020. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 22:09 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 52,752 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037385 · doc4.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,968 F1 · shares: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on June 15, 2021, subject to the Reporting Person remaining a service provider through such date. Read SEC document |
| June 03, 2020 Filed Jun 17, 2020 20:17 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001420506-20-000699 · doc4_811.xml · derivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2021 annual meeting of stockholders. Read SEC document |
| May 20, 2020 Filed May 22, 2020 12:23 UTC | AtriCure, Inc. ATRC · Entity 2704 | GrantCommon Stock | 2,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-031558 · doc4.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,122 F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2014 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:01 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 92,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-027045 · doc4.xml · nonDerivative · entry 2 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,216 F2 · shares: These shares are RSUs and 1/36th of the RSUs shall vest on each monthly anniversary measured from May 1, 2020 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person remaining a service provider through each such vesting date. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:01 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 7,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-027045 · doc4.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,111 F1 · shares: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on June 12, 2020, subject to the Reporting Person remaining a service provider through such date. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:10 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,400 | $3.57 | $4,998.00 |
DisclosureSEC source: 0001420506-20-000357 · doc4_797.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,691 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.57 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2020. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 22:06 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 1,008 | $4.96 | $4,999.68 |
DisclosureSEC source: 0001420506-20-000012 · doc4_785.xml · nonDerivative · entry 1 JOHNSON B KRISTINE · CIK 0001231984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,291 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $4.96 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.